This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on X or LinkedIn  


Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema

OXU-001 represents potential best-in-class treatment for DME with just one, targeted administration per year Initiation of OXEYE Phase 2 clinical trial of OXU-001 in DME patients on-track for first quarter of 2023; Initial clinical data on safety and durability expected in 2023 January 24, 2023 08:00 AM Eastern Standard Time OXFORD, United Kingdom--(BUSINESS WIRE)--Oxular Limited, a clinical-stage ophthalmic company developing... Read more

First-in-human clinical data shows SonoTran® is safe and well-tolerated

Data presented at the European Symposium on Ultrasound Contrast Imaging also demonstrated consistent SonoTran® Particle activation Recruitment underway for Delivery and Efficacy cohorts of Phase 1/2a proof of concept study Oxford, UK – 23 January 2023 – OxSonics Therapeutics, a clinical-stage medtech company focused on transforming cancer treatment through SonoTran®, its proprietary ultrasound-based drug delivery platform, today announces... Read more

Acquisition of Hinshelwood Building to provide additional space at TOSP

Acquisition of Hinshelwood Building to provide additional space at TOSP Oxford, UK, January 23 2023 –The Oxford Science Park (TOSP), one of Europe's leading locations for science and technology companies, has further expanded its capacity to accommodate innovative firms with the acquisition of the Hinshelwood Building. The 31,581 sq ft building is situated at the centre of the Park. The transaction is part of The Oxford Science Park’s... Read more

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

Oxford, UK, 05 January 2023: Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes. The... Read more

Celleron Therapeutics and Argonaut Therapeutics Announce Completion of Merger to Form IngenOx Therapeutics

Oxford, UK – 5 January 2023 Celleron Therapeutics and Argonaut Therapeutics have jointly announced today the completion of a merger agreement to form IngenOx Therapeutics (www.ingenox.com). Supported by Oxford Science Enterprises (OSE), the merger of the two University of Oxford spinout companies brings together drug discovery and clinical development capabilities, which streamlines the R&D process and ensures pipeline... Read more

The Daubeny Project

Imaginative design, inspiring spaces.